{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T04:08:06Z","timestamp":1775534886906,"version":"3.50.1"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T00:00:00Z","timestamp":1708041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T00:00:00Z","timestamp":1708041600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["HNO"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1007\/s00106-024-01428-9","type":"journal-article","created":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T15:02:33Z","timestamp":1708095753000},"page":"788-799","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Chronische Rhinosinusitis bei Menschen mit zystischer Fibrose\u00a0\u2013 eine aktuelle \u00dcbersicht aus der Perspektive der Hals\u2011, Nasen\u2011, Ohrenheilkunde","Chronic rhinosinusitis in people with cystic fibrosis\u2014an up-to-date review from the perspective of otorhinolaryngology"],"prefix":"10.1007","volume":"72","author":[{"given":"M.","family":"Y\u0131lmaz Top\u00e7uo\u011flu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Sommerburg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. O.","family":"Wielp\u00fctz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Wucherpfennig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Hackenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. G.","family":"Mainz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Baumann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,2,16]]},"reference":[{"key":"1428_CR1","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S2213-2600(19)30337-6","volume":"8","author":"SC Bell","year":"2020","unstructured":"Bell\u00a0SC, Mall\u00a0MA, Gutierrez\u00a0H et\u00a0al (2020) The future of cystic fibrosis care: a\u00a0global perspective. Lancet Respir Med 8:65\u2013124","journal-title":"Lancet Respir Med"},{"key":"1428_CR2","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/j.jcf.2016.03.004","volume":"15","author":"MC Berkhout","year":"2016","unstructured":"Berkhout\u00a0MC, Klerx-Melis\u00a0F, Fokkens\u00a0WJ et\u00a0al (2016) CT-abnormalities, bacteriology and symptoms of sinonasal disease in children with cystic fibrosis. J\u00a0Cyst Fibros 15:816\u2013824","journal-title":"J Cyst Fibros"},{"key":"1428_CR3","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1513\/AnnalsATS.202101-057OC","volume":"19","author":"DM Beswick","year":"2022","unstructured":"Beswick\u00a0DM, Humphries\u00a0SM, Balkissoon\u00a0CD et\u00a0al (2022) Impact of cystic fibrosis transmembrane conductance regulator therapy on chronic rhinosinusitis and health status: deep learning CT analysis and patient-reported outcomes. Ann Am Thorac Soc 19:12\u201319","journal-title":"Ann Am Thorac Soc"},{"key":"1428_CR4","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1002\/alr.23016","volume":"12","author":"DM Beswick","year":"2022","unstructured":"Beswick\u00a0DM, Humphries\u00a0SM, Miller\u00a0JE et\u00a0al (2022) Objective and patient-based measures of chronic rhinosinusitis in people with cystic fibrosis treated with highly effective modulator therapy. Int Forum Allergy Rhinol 12:1435\u20131438","journal-title":"Int Forum Allergy Rhinol"},{"key":"1428_CR5","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1002\/ppul.23613","volume":"52","author":"JM Bock","year":"2017","unstructured":"Bock\u00a0JM, Schien\u00a0M, Fischer\u00a0C et\u00a0al (2017) Importance to question sinonasal symptoms and to perform rhinoscopy and rhinomanometry in cystic fibrosis patients. Pediatr Pulmonol 52:167\u2013174","journal-title":"Pediatr Pulmonol"},{"key":"1428_CR6","doi-asserted-by":"publisher","first-page":"3271","DOI":"10.1007\/s00405-023-07859-4","volume":"280","author":"SFN Bode","year":"2023","unstructured":"Bode\u00a0SFN, Rapp\u00a0H, Lienert\u00a0N et\u00a0al (2023) Effects of CFTR-modulator triple therapy on sinunasal symptoms in children and adults with cystic fibrosis. Eur Arch Otorhinolaryngol 280:3271\u20133277","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"1428_CR7","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1097\/00005537-199903000-00010","volume":"109","author":"WM Boek","year":"1999","unstructured":"Boek\u00a0WM, Kele\u015f\u00a0N, Graamans\u00a0K et\u00a0al (1999) Physiologic and hypertonic saline solutions impair ciliary activity in vitro. Laryngoscope 109:396\u2013399","journal-title":"Laryngoscope"},{"key":"1428_CR8","volume-title":"S3-Leitlinie Lungenerkrankung bei Mukoviszidose: Pseudomonas Aeruginosa","author":"Deutsche Gesellschaft F\u00fcr Pneumologie Und Beatmungsmedizin (Dgp) \/ Gesellschaft F\u00fcr P\u00e4diatrische Pneumologie E.\u202fV. (Gpp)","year":"2022","unstructured":"Deutsche Gesellschaft F\u00fcr Pneumologie Und Beatmungsmedizin (Dgp) \/ Gesellschaft F\u00fcr P\u00e4diatrische Pneumologie E.\u202fV. (Gpp) (2022) S3-Leitlinie Lungenerkrankung bei Mukoviszidose: Pseudomonas Aeruginosa. AWMF-Leitlinie"},{"key":"1428_CR9","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.jcf.2020.07.002","volume":"20","author":"E Dimango","year":"2021","unstructured":"Dimango\u00a0E, Overdevest\u00a0J, Keating\u00a0C et\u00a0al (2021) Effect of highly effective modulator treatment on sinonasal symptoms in cystic fibrosis. J\u00a0Cyst Fibros 20:460\u2013463","journal-title":"J Cyst Fibros"},{"key":"1428_CR10","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/alr.22700","volume":"11","author":"E Dimango","year":"2021","unstructured":"Dimango\u00a0E, Spielman\u00a0DB, Overdevest\u00a0J et\u00a0al (2021) Effect of highly effective modulator therapy on quality of life in adults with cystic fibrosis. Int Forum Allergy Rhinol 11:75\u201378","journal-title":"Int Forum Allergy Rhinol"},{"key":"1428_CR11","doi-asserted-by":"publisher","first-page":"154","DOI":"10.3109\/02841859909177731","volume":"40","author":"HB Eggesb\u00f8","year":"1999","unstructured":"Eggesb\u00f8\u00a0HB, Ringertz\u00a0S, Haanaes\u00a0OC et\u00a0al (1999) CT and MR imaging of the paranasal sinuses in cystic fibrosis. Correlation with microbiological and histopathological results. Acta Radiol 40:154\u2013162","journal-title":"Acta Radiol"},{"key":"1428_CR12","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1080\/028418501127347214","volume":"42","author":"HB Eggesb\u00f8","year":"2001","unstructured":"Eggesb\u00f8\u00a0HB, S\u00f8vik\u00a0S, D\u00f8lvik\u00a0S et\u00a0al (2001) CT characterization of developmental variations of the paranasal sinuses in cystic fibrosis. Acta Radiol 42:482\u2013493","journal-title":"Acta Radiol"},{"key":"1428_CR13","doi-asserted-by":"publisher","first-page":"103858","DOI":"10.1016\/j.amjoto.2023.103858","volume":"44","author":"E Eischen","year":"2023","unstructured":"Eischen\u00a0E, Gliksman\u00a0MF, Segarra\u00a0D et\u00a0al (2023) Correlation between CT imaging and symptom scores in cystic fibrosis associated chronic sinusitis. Am J Otolaryngol 44:103858","journal-title":"Am J Otolaryngol"},{"issue":"4","key":"1428_CR14","doi-asserted-by":"publisher","first-page":"401","DOI":"10.3390\/genes11040401","volume":"11","author":"PM Farrell","year":"2020","unstructured":"Farrell PM, Rock MJ, Baker MW (2020) The impact of the CFTR gene discovery on cystic fibrosis diagnosis, counseling, and preventive therapy. Genes 11(4):401","journal-title":"Genes"},{"key":"1428_CR15","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1002\/ppul.22982","volume":"49","author":"N Fischer","year":"2014","unstructured":"Fischer\u00a0N, Hentschel\u00a0J, Markert\u00a0UR et\u00a0al (2014) Non-invasive assessment of upper and lower airway infection and inflammation in CF patients. Pediatr Pulmonol 49:1065\u20131075","journal-title":"Pediatr Pulmonol"},{"key":"1428_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4193\/Rhin20.401","volume":"58","author":"WJ Fokkens","year":"2020","unstructured":"Fokkens\u00a0WJ, Lund\u00a0VJ, Hopkins\u00a0C et\u00a0al (2020) European position paper on rhinosinusitis and nasal polyps 2020. Rhinology 58:1\u2013464","journal-title":"Rhinology"},{"key":"1428_CR17","volume-title":"S3-Leitlinie Mukoviszidose bei Kindern in den ersten beiden Lebensjahren, Diagnostik und Therapie","author":"Gesellschaft F\u00fcr P\u00e4diatrische Pneumologie E.\u202fV. (Gpp)","year":"2019","unstructured":"Gesellschaft F\u00fcr P\u00e4diatrische Pneumologie E.\u202fV. (Gpp), Deutsche Gesellschaft F\u00fcr Kinder- Und Jugendmedizin E.\u202fV. (Dgkj) (2019) S3-Leitlinie Mukoviszidose bei Kindern in den ersten beiden Lebensjahren, Diagnostik und Therapie. AWMF-Leitlinie"},{"key":"1428_CR18","doi-asserted-by":"publisher","first-page":"3595","DOI":"10.1002\/ppul.25627","volume":"56","author":"DM Goetz","year":"2021","unstructured":"Goetz\u00a0DM, Savant\u00a0AP (2021) Review of CFTR modulators 2020. Pediatr Pulmonol 56:3595\u20133606","journal-title":"Pediatr Pulmonol"},{"key":"1428_CR19","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1164\/rccm.202110-2249OC","volume":"205","author":"SY Graeber","year":"2022","unstructured":"Graeber\u00a0SY, Vitzthum\u00a0C, Pallenberg\u00a0ST et\u00a0al (2022) Effects of elexacaftor\/tezacaftor\/ivacaftor therapy on CFTR function in patients with cystic fibrosis and one or two F508del alleles. Am J Respir Crit Care Med 205:540\u2013549","journal-title":"Am J Respir Crit Care Med"},{"key":"1428_CR20","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1513\/AnnalsATS.201408-393OC","volume":"12","author":"AR Habib","year":"2015","unstructured":"Habib\u00a0AR, Buxton\u00a0JA, Singer\u00a0J et\u00a0al (2015) Association between chronic rhinosinusitis and health-related quality of life in adults with cystic fibrosis. Ann Am Thorac Soc 12:1163\u20131169","journal-title":"Ann Am Thorac Soc"},{"key":"1428_CR21","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","volume":"394","author":"HGM Heijerman","year":"2019","unstructured":"Heijerman\u00a0HGM, Mckone\u00a0EF, Downey\u00a0DG et\u00a0al (2019) Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a\u00a0double-blind, randomised, phase\u00a03\u00a0trial. Lancet 394:1940\u20131948","journal-title":"Lancet"},{"key":"1428_CR22","first-page":"Cd012979","volume":"4","author":"TK Karanth","year":"2022","unstructured":"Karanth\u00a0TK, Karanth\u00a0V, Ward\u00a0BK et\u00a0al (2022) Medical interventions for chronic rhinosinusitis in cystic fibrosis. Cochrane Database Syst Rev 4:Cd12979","journal-title":"Cochrane Database Syst Rev"},{"key":"1428_CR23","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1067\/mhn.2003.41","volume":"128","author":"DJ Kay","year":"2003","unstructured":"Kay\u00a0DJ, Rosenfeld\u00a0RM (2003) Quality of life for children with persistent sinonasal symptoms. Otolaryngol Head Neck Surg 128:17\u201326","journal-title":"Otolaryngol Head Neck Surg"},{"key":"1428_CR24","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1126\/science.2570460","volume":"245","author":"B Kerem","year":"1989","unstructured":"Kerem\u00a0B, Rommens\u00a0JM, Buchanan\u00a0JA et\u00a0al (1989) Identification of the cystic fibrosis gene: genetic analysis. Science 245:1073\u20131080","journal-title":"Science"},{"key":"1428_CR25","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1002\/alr.22974","volume":"12","author":"AJ Kimple","year":"2022","unstructured":"Kimple\u00a0AJ, Senior\u00a0BA, Naureckas\u00a0ET et\u00a0al (2022) Cystic fibrosis foundation otolaryngology care multidisciplinary consensus recommendations. Int Forum Allergy Rhinol 12:1089\u20131103","journal-title":"Int Forum Allergy Rhinol"},{"key":"1428_CR26","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s00106-005-1328-9","volume":"54","author":"A Koitschev","year":"2006","unstructured":"Koitschev\u00a0A, Wolff\u00a0A, Koitschev\u00a0C et\u00a0al (2006) Standardisierte HNO-Untersuchung bei Patienten mit Mukoviszidose. HNO 54:361\u2013368","journal-title":"HNO"},{"key":"1428_CR27","unstructured":"Deutsches Mukoviszidose-Register Berichtsband 2021. In: N\u00e4hrlich L (Hrsg) Deutsches Mukoviszidose-Register"},{"key":"1428_CR28","unstructured":"Deutsches Mukoviszidose-Register Berichtsband 2022. In: N\u00e4hrlich L (Hrsg) Deutsches Mukoviszidose-Register"},{"key":"1428_CR29","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.jcf.2022.05.008","volume":"21","author":"DJ Lee","year":"2022","unstructured":"Lee\u00a0DJ, Sykes\u00a0J, Griffin\u00a0K et\u00a0al (2022) The negative impact of chronic rhinosinusitis on the health-related quality of life among adult patients with cystic fibrosis. J\u00a0Cyst Fibros 21:800\u2013806","journal-title":"J Cyst Fibros"},{"key":"1428_CR30","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1002\/alr.21190","volume":"3","author":"J Liang","year":"2013","unstructured":"Liang\u00a0J, Higgins\u00a0TS, Ishman\u00a0SL et\u00a0al (2013) Surgical management of chronic rhinosinusitis in cystic fibrosis: a\u00a0systematic review. Int Forum Allergy Rhinol 3:814\u2013822","journal-title":"Int Forum Allergy Rhinol"},{"key":"1428_CR31","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1007\/s00405-012-2124-2","volume":"270","author":"J Lindig","year":"2013","unstructured":"Lindig\u00a0J, Steger\u00a0C, Beiersdorf\u00a0N et\u00a0al (2013) Smell in cystic fibrosis. Eur Arch Otorhinolaryngol 270:915\u2013921","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"1428_CR32","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1177\/000348949510410s02","volume":"167","author":"VJ Lund","year":"1995","unstructured":"Lund\u00a0VJ, Kennedy\u00a0DW (1995) Quantification for staging sinusitis. The staging and therapy group. Ann Otol Rhinol Laryngol Suppl 167:17\u201321","journal-title":"Ann Otol Rhinol Laryngol Suppl"},{"key":"1428_CR33","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1007\/s00405-019-05308-9","volume":"276","author":"P Luparello","year":"2019","unstructured":"Luparello\u00a0P, Lazio\u00a0MS, Voltolini\u00a0L et\u00a0al (2019) Outcomes of endoscopic sinus surgery in adult lung transplant patients with cystic fibrosis. Eur Arch Otorhinolaryngol 276:1341\u20131347","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"1428_CR34","doi-asserted-by":"publisher","first-page":"642180","DOI":"10.3389\/fimmu.2021.642180","volume":"12","author":"JG Mainz","year":"2021","unstructured":"Mainz\u00a0JG, Arnold\u00a0C, Wittstock\u00a0K et\u00a0al (2021) Ivacaftor reduces inflammatory mediators in upper airway lining fluid from cystic fibrosis patients with a\u00a0G551D mutation: serial non-invasive home-based collection of upper airway lining fluid. Front Immunol 12:642180","journal-title":"Front Immunol"},{"key":"1428_CR35","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s00106-015-0069-7","volume":"63","author":"JG Mainz","year":"2015","unstructured":"Mainz\u00a0JG, Gerber\u00a0A, Arnold\u00a0C et\u00a0al (2015) Rhinosinusitis bei Mukoviszidose. HNO 63:809\u2013820","journal-title":"HNO"},{"key":"1428_CR36","first-page":"438517","volume":"2015","author":"JG Mainz","year":"2015","unstructured":"Mainz\u00a0JG, Gerber\u00a0A, Lorenz\u00a0M et\u00a0al (2015) Pseudomonas aeruginosa acquisition in cystic fibrosis patients in context of otorhinolaryngological surgery or dentist attendance: case series and discussion of preventive concepts. Case Rep Infect Dis 2015:438517","journal-title":"Case Rep Infect Dis"},{"key":"1428_CR37","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1016\/S1569-1993(09)60005-9","volume":"8","author":"JG Mainz","year":"2009","unstructured":"Mainz\u00a0JG, Koitschev\u00a0A (2009) Management of chronic rhinosinusitis in CF. J\u00a0Cyst Fibros 8:S10\u2013S14","journal-title":"J Cyst Fibros"},{"key":"1428_CR38","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s11882-012-0250-y","volume":"12","author":"JG Mainz","year":"2012","unstructured":"Mainz\u00a0JG, Koitschev\u00a0A (2012) Pathogenesis and management of nasal polyposis in cystic fibrosis. Curr Allergy Asthma Rep 12:163\u2013174","journal-title":"Curr Allergy Asthma Rep"},{"key":"1428_CR39","doi-asserted-by":"crossref","unstructured":"Mainz JG, Lester K, Elnazir B et al (2023) Reduction in abdominal symptoms (CFAbd-Score), faecal M2-pyruvate-kinase and calprotectin over one year of treatment with elexacaftor-tezacaftor-ivacaftor in people with CF aged \u2265\u202f12 years\u2014The RECOVER study. J Cyst Fibros 7:S1569\u20131993(23)00922-0","DOI":"10.1101\/2023.07.10.23292435"},{"key":"1428_CR40","doi-asserted-by":"publisher","first-page":"209","DOI":"10.2147\/DDDT.S54064","volume":"8","author":"JG Mainz","year":"2014","unstructured":"Mainz\u00a0JG, Sch\u00e4dlich\u00a0K, Schien\u00a0C et\u00a0al (2014) Sinonasal inhalation of tobramycin vibrating aerosol in cystic fibrosis patients with upper airway Pseudomonas aeruginosa colonization: results of a\u00a0randomized, double-blind, placebo-controlled pilot study. Drug Des Devel Ther 8:209\u2013217","journal-title":"Drug Des Devel Ther"},{"key":"1428_CR41","doi-asserted-by":"publisher","first-page":"877118","DOI":"10.3389\/fphar.2022.877118","volume":"13","author":"JG Mainz","year":"2022","unstructured":"Mainz\u00a0JG, Zagoya\u00a0C, Polte\u00a0L et\u00a0al (2022) Elexacaftor-tezacaftor-ivacaftor treatment reduces abdominal symptoms in cystic fibrosis-early results obtained with the CF-specific CFAbd-score. Front Pharmacol 13:877118","journal-title":"Front Pharmacol"},{"key":"1428_CR42","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1089\/jamp.2007.0659","volume":"21","author":"MA Mall","year":"2008","unstructured":"Mall\u00a0MA (2008) Role of cilia, mucus, and airway surface liquid in mucociliary dysfunction: lessons from mouse models. J\u00a0Aerosol Med Pulm Drug Deliv 21:13\u201324","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"key":"1428_CR43","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.biocel.2014.02.006","volume":"52","author":"MA Mall","year":"2014","unstructured":"Mall\u00a0MA, Graeber\u00a0SY, Stahl\u00a0M et\u00a0al (2014) Early cystic fibrosis lung disease: Role of airway surface dehydration and lessons from preventive rehydration therapies in mice. Int J Biochem Cell Biol 52:174\u2013179","journal-title":"Int J Biochem Cell Biol"},{"key":"1428_CR44","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1183\/09031936.00228013","volume":"44","author":"MA Mall","year":"2014","unstructured":"Mall\u00a0MA, Hartl\u00a0D (2014) CFTR: cystic fibrosis and beyond. Eur Respir\u00a0J 44:1042\u20131054","journal-title":"Eur Respir J"},{"key":"1428_CR45","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1164\/rccm.201910-1943SO","volume":"201","author":"MA Mall","year":"2020","unstructured":"Mall\u00a0MA, Mayer-Hamblett\u00a0N, Rowe\u00a0SM (2020) Cystic fibrosis: emergence of highly effective targeted therapeutics and potential clinical implications. Am J Respir Crit Care Med 201:1193\u20131208","journal-title":"Am J Respir Crit Care Med"},{"key":"1428_CR46","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","volume":"381","author":"PG Middleton","year":"2019","unstructured":"Middleton\u00a0PG, Mall\u00a0MA, D\u0159ev\u00ednek\u00a0P et\u00a0al (2019) Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a\u00a0single Phe508del allele. N\u00a0Engl J Med 381:1809\u20131819","journal-title":"N Engl J Med"},{"key":"1428_CR47","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1164\/rccm.202108-1986OC","volume":"205","author":"DP Nichols","year":"2022","unstructured":"Nichols\u00a0DP, Paynter\u00a0AC, Heltshe\u00a0SL et\u00a0al (2022) Clinical effectiveness of elexacaftor\/tezacaftor\/Ivacaftor in people with cystic fibrosis: a\u00a0clinical trial. Am J Respir Crit Care Med 205:529\u2013539","journal-title":"Am J Respir Crit Care Med"},{"key":"1428_CR48","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1002\/alr.22741","volume":"11","author":"RR Orlandi","year":"2021","unstructured":"Orlandi\u00a0RR, Kingdom\u00a0TT, Smith\u00a0TL et\u00a0al (2021) International consensus statement on allergy and rhinology: rhinosinusitis 2021. Int Forum Allergy Rhinol 11:213\u2013739","journal-title":"Int Forum Allergy Rhinol"},{"key":"1428_CR49","doi-asserted-by":"publisher","first-page":"2216","DOI":"10.1002\/lary.24654","volume":"124","author":"AJ Psaltis","year":"2014","unstructured":"Psaltis\u00a0AJ, Li\u00a0G, Vaezeafshar\u00a0R et\u00a0al (2014) Modification of the Lund-Kennedy endoscopic scoring system improves its reliability and correlation with patient-reported outcome measures. Laryngoscope 124:2216\u20132223","journal-title":"Laryngoscope"},{"issue":"2","key":"1428_CR50","first-page":"32","volume":"7","author":"C Safi","year":"2019","unstructured":"Safi C, Zheng Z, Dimango E et al (2019) Chronic rhinosinusitis in cystic fibrosis: diagnosis and medical management. Med Sci 7(2):32","journal-title":"Med Sci"},{"key":"1428_CR51","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/1477-7525-7-97","volume":"7","author":"A Schmidt","year":"2009","unstructured":"Schmidt\u00a0A, Wenninger\u00a0K, Niemann\u00a0N et\u00a0al (2009) Health-related quality of life in children with cystic fibrosis: validation of the German CFQ\u2011R. Health Qual Life Outcomes 7:97","journal-title":"Health Qual Life Outcomes"},{"key":"1428_CR52","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1007\/s00117-022-01076-6","volume":"62","author":"O Sommerburg","year":"2022","unstructured":"Sommerburg\u00a0O, Wielp\u00fctz\u00a0MO (2022) Update on cystic fibrosis : from neonatal screening to causal treatment. Radiologie 62:981\u2013994","journal-title":"Radiologie"},{"key":"1428_CR53","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1513\/AnnalsATS.201910-777OC","volume":"17","author":"O Sommerburg","year":"2020","unstructured":"Sommerburg\u00a0O, Wielp\u00fctz\u00a0MO, Trame\u00a0JP et\u00a0al (2020) Magnetic resonance imaging detects chronic rhinosinusitis in infants and preschool children with cystic fibrosis. Ann Am Thorac Soc 17:714\u2013723","journal-title":"Ann Am Thorac Soc"},{"key":"1428_CR54","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1007\/s00117-020-00728-9","volume":"60","author":"M Stahl","year":"2020","unstructured":"Stahl\u00a0M (2020) Clinical presentation of lung disease in cystic fibrosis. Radiologe 60:774\u2013780","journal-title":"Radiologe"},{"key":"1428_CR55","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.jcf.2022.03.002","volume":"21","author":"AL Stapleton","year":"2022","unstructured":"Stapleton\u00a0AL, Kimple\u00a0AJ, Goralski\u00a0JL et\u00a0al (2022) Elexacaftor-tezacaftor-ivacaftor improves sinonasal outcomes in cystic fibrosis. J\u00a0Cyst Fibros 21:792\u2013799","journal-title":"J Cyst Fibros"},{"key":"1428_CR56","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/j.jcf.2022.03.011","volume":"21","author":"L Wucherpfennig","year":"2022","unstructured":"Wucherpfennig\u00a0L, Triphan\u00a0SMF, Wege\u00a0S et\u00a0al (2022) Magnetic resonance imaging detects improvements of pulmonary and paranasal sinus abnormalities in response to elexacaftor\/tezacaftor\/ivacaftor therapy in adults with cystic fibrosis. J\u00a0Cyst Fibros 21:1053\u20131060","journal-title":"J Cyst Fibros"},{"key":"1428_CR57","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1513\/AnnalsATS.202209-763OC","volume":"20","author":"L Wucherpfennig","year":"2023","unstructured":"Wucherpfennig\u00a0L, Wuennemann\u00a0F, Eichinger\u00a0M et\u00a0al (2023) Longitudinal magnetic resonance imaging detects onset and progression of chronic rhinosinusitis from infancy to school age in cystic fibrosis. Ann Am Thorac Soc 20:687\u2013697","journal-title":"Ann Am Thorac Soc"},{"key":"1428_CR58","doi-asserted-by":"publisher","first-page":"1161891","DOI":"10.3389\/fphar.2023.1161891","volume":"14","author":"L Wucherpfennig","year":"2023","unstructured":"Wucherpfennig\u00a0L, Wuennemann\u00a0F, Eichinger\u00a0M et\u00a0al (2023) Long-term effects of lumacaftor\/ivacaftor on paranasal sinus abnormalities in children with cystic fibrosis detected with magnetic resonance imaging. Front Pharmacol 14:1161891","journal-title":"Front Pharmacol"},{"issue":"4","key":"1428_CR59","first-page":"57","volume":"7","author":"Z Zheng","year":"2019","unstructured":"Zheng Z, Safi C, Gudis DA (2019) Surgical management of chronic rhinosinusitis in cystic fibrosis. Med Sci 7(4):57","journal-title":"Med Sci"}],"container-title":["HNO"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00106-024-01428-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00106-024-01428-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00106-024-01428-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T15:02:26Z","timestamp":1729695746000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00106-024-01428-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,16]]},"references-count":59,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["1428"],"URL":"https:\/\/doi.org\/10.1007\/s00106-024-01428-9","relation":{},"ISSN":["0017-6192","1433-0458"],"issn-type":[{"value":"0017-6192","type":"print"},{"value":"1433-0458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,16]]},"assertion":[{"value":"12 December 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"M.O. Wielp\u00fctz gibt an, Studienf\u00f6rderung von Vertex Pharmaceuticals und Konsultationen Vertex Pharmaceuticals und B\u00f6hringer Ingelheim Pharma (Drittmittel) zu erhalten. M.\u00a0Y\u0131lmaz Top\u00e7uo\u011flu, O.\u00a0Sommerburg, L.\u00a0Wucherpfennig, S.\u00a0Hackenberg, J.G.\u00a0Mainz und I.\u00a0Baumann geben an, dass keine Interessenkonflikte bestehen.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Alle beschriebenen Untersuchungen am Menschen oder an menschlichem Gewebe wurden mit Zustimmung der zust\u00e4ndigen Ethikkommission, im Einklang mit nationalem Recht sowie gem\u00e4\u00df der Deklaration von Helsinki von 1975 (in der aktuellen, \u00fcberarbeiteten Fassung) durchgef\u00fchrt. Von allen beteiligten Patient\/-innen liegt eine Einverst\u00e4ndniserkl\u00e4rung vor.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}